Preparation and evaluation of chitosan based thermoreversible gels for intraperitoneal delivery of 5-fluorouracil (5-FU

Acta Pharmaceutica

Volumn 63, Issue 4, 2013, Pages 479-491

  Depani, Bhavesh P ^a   Naik, Anuja A ^a   Nair, Hema A ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

5 fluorouracil; Chitosan; Glycerophosphate; Intraperitoneal; Thermoreversible gels

Indexed keywords

CHITOSAN; FLUOROURACIL; GLYCEROPHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER SIZE; CANCER SURVIVAL; COLON; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; FIBROBLAST; GEL; IN VITRO STUDY; IN VIVO STUDY; MORTALITY; MOUSE; NONHUMAN; TREATMENT DURATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CHITOSAN; COLONIC NEOPLASMS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FIBROBLASTS; FLUOROURACIL; GELS; GLYCEROL; INJECTIONS, INTRAPERITONEAL; LETHAL DOSE 50; MALE; MICE; MICE, INBRED BALB C; TOXICITY TESTS, ACUTE; TUMOR BURDEN;

EID: 84896114570     PISSN: 13300075     EISSN: 18469558     Source Type: Journal    
DOI: 10.2478/acph-2013-0033     Document Type: Article

References (23)

1. S. C. Sweetman, Martindale the Complete Drug Reference (Ed. S. C. Sweetman), 34th ed., Pharmaceutical Press, London 2005, pp. 554-556.
2. E. Reed, J. Jacob, R. F. Ozols, R. C. Young and C. Allegra, 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma, Gynecol. Oncol. 46 (1992) 326-329; DOI: 10.1016/0090-8258(92) 90226-9.
3. www.rxlist.com, accessed on 25th July 2011.
4. A. Goodman and L. Gilman, Antineoplastic Agents, in Manual of Pharmacology and Therapeutics (Ed. K. Parker), 11th ed., McGraw Hill, New York 2008, pp. 874-876.
5. M. Markman, Intraperitoneal antineoplastic drug delivery: rationale and results, Lancet Oncol. 4 (2003) 277-283; DOI: 10.1016/S1470-2045(03)01074-X.
6. A. Chenite, M. Buschmann, D. Wang, C. Chaput and N. Kandani, Rheological characterisation of thermogelling chitosan/glycerol-phosphate solutions, Carbohydr. Polym. 46 (2001) 39-47; DOI: 10.1016/S0144-8617(00)00281-2.
7. W. Jie, S. Zhi-Guo and M. Guang-Hui, A thermo-and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate, Int. J. Pharm. 315 (2006) 1-11; DOI: 10.1016/j.ijpharm.2006. 01.04.
8. Y. Wang, N. Xu, Q. Luo, Y. Li, L. Sun, H. Wang, K. Xu, B. Wang and Y. Zhen, In vivo assessment of chitosan/â-glycerophosphate as a new liquid embolic agent, Interv. Neuroradiol. 17 (2011) 87-92.
9. E. Ruel-Gariepy and L. Jean-Christophe, In situ-forming hydrogels-review of temperature-sensitive systems, Eur. J. Pharm. Biopharm. 58 (2004) 409-426; DOI: 10.1016/j.ejpb.2004.03.019.
10. E. Ruel-Gariepy, A. Chenite, C. Chaput, S. Guirguis and J. Leroux, Characterization of thermosensitive chitosan gels for the sustained delivery of drugs, Int. J. Pharm. 203 (2000) 89-98; DOI: 10.1016/S0378-5173(00)00428-2.
11. OECD guideline 425 for the testing of chemicals. Section 4, Acute Oral Toxicity: Up-and-Down Procedure.
12. G. Carlsson, B. Gullberg and L. Hafstrom, Estimation of liver tumor volume using different formulas -an experimental study in rats, J. Cancer Res. Clin. Oncol. 105 (1983) 20-23; DOI: 10.1007/ BF00391826.
13. M. M. Tomayko and C. P. Reynolds, Determination of subcutaneous tumor size in athymic (nude) mice, Cancer Chemother. Pharmacol. 24 (1989) 148-154; DOI: 10.1007/BF00300234.
14. B. Jeong, S. W. Kim and Y. H. Bae, Thermosensitive sol-gel reversible hydrogels, Adv. Drug Deliv. Rev. 54 (2002) 37-51; DOI: 10.1016/S0169-409X(01) 00242-3.
15. F. Ganji, M Abdekhodaie and S. A. Ramazani, Gelation time and degradation rate of chitosan-based injectable hydrogel, J. Sol-Gel Sci. Tech. 42 (2007) 47-53; DOI: 10.1007/s10971-006-9007-1.
16. D. Anderson and D. M. Conning, Experimental Toxicology: the Basic Issues, 2nd ed., Royal Society of Chemistry, California 1993, p. 17.
17. A. M. Fan, L. W. Chang, Toxicology and Risk Assessment; Principles, Methods and Application, 4th ed., Marcel Dekker Inc., New York 1996, pp. 108-110.
18. J. L. Speyer, P. H. Sugarbaker, J. M. Collins, R. L. Dedrick, R. W. Klecker and C. E. Myers, Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans, Cancer Res. 41 (1981) 1916-1922.
19. M. J. Ellenhorn, Ellenhorn's Medicinal Toxicology; Diagnosis and Treatment of Human Poisoning (Ed. M. J. Ellenhorn), 2nd ed., Williams and Wilkins, Baltimore 1997, p. 1326.
20. R. L. Schilsky, K. E. Choi, J. Grayhack, D. Grimmer, C. Guarnieri and L. Fullem, Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intra-abdominal cancer, J. Clin Oncol. 8 (1990) 2054-2061.
21. M. Ravi Kumar, R. Muzzarelli and C. Muzzarelli, Chitosan chemistry and pharmaceutical perspectives, Chem. Rev. 104 (2004) 6017-6084; DOI: 10.1002/chin.200511296.
22. R. Zange, Y. Li and T. Kissel, Biocompatibility testing of ABA triblock copolymers consisting of poly (L-lactic-co-glycolic acid) A blocks attached to a central poly(ethylene oxide) B block under in vitro conditions using different L929 mouse fibroblasts cell culture models, J. Control. Release 56 (1998) 249-258; DOI: 10.1016/S0168-3659(98)00093-5.
23. R. Ahmadi, M. Zhou, J. D. De Bruijn, The use of thermo-sensitive chitosan as an injectable carrier for bone tissue engineering, Eur. Cell Mater. 10 (2005) 61.